Eric Lefkofsky, CEO and founder of Tempus AI, explains to Scottish Mortgage manager Tom Slater the huge potential in personalising cancer diagnosis and treatment at scale. Capital at risk.

Tempus AI (NASDAQ: TEM) is utilizing artificial intelligence to deliver better healthcare outcomes. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

Private Advisor Group LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) during the fourth ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was up 12.7% on Wednesday after Needham & Company LLC raised their price target on the stock from $56.00 to $70.00. Needham & Company LLC currently has a ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Popular investor Cathie Wood and her Ark Invest funds took advantage of a buying opportunity on Tuesday by purchasing over 400,000 shares of ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Cathie Wood and Ark Invest moved to acquire Transfus AI (TEM, Financial) shares after its share price dropped by 1.5%. Wood's ...

Cathie Wood and Ark Invest seized the opportunity on Tuesday to buy the dip on Tempus AI (NASDAQ:TEM) as the stock took a 15% ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an emerging AI player in the healthcare field with a robust outlook ...